



NDA 201699/S-004

SUPPLEMENT APPROVAL

Optimer Pharmaceuticals, Inc.
Attention: Antonia Kolokathis, M.D.
Senior Vice President, Chief Medical Officer
4755 Nexus Center Drive
San Diego, CA 92121

Dear Dr. Kolokathis:

Please refer to your Supplemental New Drug Application (sNDA) dated October 8, 2012, received October 9, 2012, submitted under 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Dificid (fidaxomicin) 200 mg Tablets.

We acknowledge receipt of your amendments dated February 22, March 18 and March 29, 2013.

This "Changes Being Effected" supplemental new drug application provides for the following revisions to the package insert:

- Contraindications Section: Addition of hypersensitivity to fidaxomicin (4)
- Warnings and Precautions Section: Addition of a new section on acute hypersensitivity reactions (5.2)

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

We note that your March 29, 2013, submission includes final printed labeling (FPL) for your package insert. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text for the package insert with the addition

of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Fariba Izadi, Pharm. D., Regulatory Health Project Manager, at (301) 796-0563.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Deputy Director for Safety
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
04/04/2013